Timothy Cope (Advisor), Larry Ream (Committee Member), Mark Rich (Committee Member)
Master of Science (MS)
There is currently no direct evidence that chemotherapy induced peripheral neuropathy (CIPN) necessarily explains the sensorimotor deficits seen in 90% patients treated with oxaliplatin (OX). Some patients develop sensory symptoms without CIPN. Our laboratory reported abnormal signaling from IA afferents in OX treated rats with no evidence of neuropathy. We hypothesized that in the absence of CIPN, the behavioral disability is associated with impaired sensory encoding in OX treated rats. The purpose of this study was to investigate the sensorimotor abilities of OX treated rats. The battery of behavioral tests was designed to address proprioception and sensorimotor integration. In the absence of CIPN, few OX rats revealed signs of decreased performance, as compared to controls. In conclusion, this study reproduced some of the results seen in the clinical studies and established a rat model, which can be used in further investigation of chronic sensorimotor symptoms of OX.
Department or Program
Department of Neuroscience, Cell Biology & Physiology
Year Degree Awarded
Copyright 2015, all rights reserved. This open access ETD is published by Wright State University and OhioLINK.